Invivyd, Inc.

Welcome to the InVivid Conference call. At this time, all participants are in a listen-only mode. After the speakers prepared remarks, there will be a question and answer session. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to Scott Young, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.

Thank you, operator. A short while ago, we issued a press release announcing our Q1 2024 financial results and recent business highlights. That press release and the slides that are being used on today's webcast can be found in the Investor section of the InVivid website under the press release and events and presentation sections respectively. Today's discussion will be led by Mark Aliyah, Chairman of InVivid Board of Directors and Chairman of the Executive Committee of the Board. He's joined by Jeremy Gowler, Interim CEO, and Chief Operating and Commercial Officer. Bill Duke, Chief Financial Officer. Dr. Robert Allen, Chief Scientific Officer. And Dr. Mark Wingers-Anh, Senior Vice President of Clinical Development and Medical Affairs. During today's discussion, we will be making forward-looking statements concerning, among other things, our corporate and commercial strategy, our research and development activities, our regulatory plans, certain financial guidance, our future prospects, and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation Reform Act and are subject to various risks, assumptions, and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only as of the date of this call, and InVivid assumes no duty to update such statements. Additional information on the risk factors that could affect InVivid's business can be found in our filings made with the US Securities and Exchange Commission, including our most recent form 10K, which is also available on our website. I will now turn the call over to Mark.

Thanks, Scott. And thank you all for joining the call. A quick housekeeping note, this will be Scott's last quarterly calls. He is moving on from InVivid to spend the summer enjoying his boat prior to potentially starting his own business. We wish him the best and thank him for his help in getting us here. Thank you, Scott. To business, turning to slide four. The last few months have been transformational for InVivid. InVivid has been built to address head on the unique scientific, medical, and social challenges presented by -CoV-2 and potentially other viruses in the future. In 2023, -CoV-2 remained a leading cause of death for Americans, and that is to say nothing of the broad medical misery imposed by this uniquely transmissible and dangerous multi-organ virus. When we talk about building a company to meet the challenges of -CoV-2, what we mean is that we believe we are pioneering a still brand new approach to antibody prophylactics and therapeutics. Engineered antibodies represent the promise of conferring to vulnerable populations the immune response to viral threats that we all wish we could have following vaccination or infection. An immune response that may be necessary for staying safe and well rather than the immune response that keeps us alive but at continuous risk. Obviously, the risk of -CoV-2 is highest for immunocompromised population who today benefit least from vaccination and represent a high disproportionate share of ongoing hospitalizations and deaths. We're starting our journey serving their needs, but see the possibility of serving broader populations as we advance our technology and strategy. Broadly, our strategy is to combine the potential for high efficacy and attractive safety of modern monoclonal antibodies or MABs directed against the -CoV-2 spike protein with the opportunity for product evolution one commonly sees in the vaccine industry. We set out on this mission because to us, it so far represents the only viable approach for bringing high value medical options to populations in need. At this point, we see an attractive commercial opportunity for PEMGARDA in the near term, a rapid compact capital efficient pathway to generating novel options for two distinct use cases, PrEP and potentially treatment, and a scientific engine devoted to repeatable, reliable, best in class molecule generation. Of course, major questions have surrounded this strategy for now almost two years, in large part regulatory and operational. We're thrilled that over the last year, we have started to answer those questions more definitively in partnership with a highly motivated and thoughtful regulator in the US Food and Drug Administration. The recent emergency use authorization for PEMGARDA for PrEP of COVID-19 in certain adults and adolescents who have moderate to severe immune compromise, and now the opportunity to file an application for EUA for treatment of mild to moderate symptomatic COVID-19 in a similar immunocompromised population, both represent the growing alignment between the core of our strategy and the posture of the major US medical authority. Our aim is to build on and expand these early successes now by innovating to improve our products on all dimensions, the resistance to evasion that can be built into them, the potency of our antibodies and accompanying improvements in dose, therapeutic index, and form factor they might offer, and the clinical data that we hope can substantiate broad use of antibody products in the future. Our agenda today is unique for a regular quarterly call. While we will review certain elements of our recent business progress, we will also provide context for the scientific and clinical thinking that underpins our corporate and commercial strategy and our enthusiasm for the future of InVivid. Because this is not an R&D day, we will move relatively quickly through some concepts and hope that as you reflect on what you hear and read, you can engage with us on a follow-up basis if it is of further use following today's call. We have heard clearly from many of you that there are gaps in your understanding of our technologies, and we would like to take this opportunity to fill in those gaps so you can understand our company better moving forward through the launch. We believe that InVivid's bespoke, proprietary, and fully integrated discovery technologies combined with potential rapid development pathways represent an impressive competitive advantage designed to keep InVivid serving vulnerable populations with high value commercial products engineered to treat and protect from serious viral threats in perpetuity. We see the technological core of this engine as substantiating the economic vision for our firm, which is to advance high value novel medicines with high speed, high capital efficiency, and high confidence to ensure that shareholders also benefit from the substantial medical value we aim to create for vulnerable populations. A few final notes before we move on with our agenda. We are well engaged in a search for a permanent CEO, but we will not comment further at this time. Also, Jeremy Gowler will comment on multiple elements of the early PEMGuard launch, but we will not be disclosing any more granular detail than that which he will walk through in his prepared remarks, nor will we comment on any early sales trends other than to say that at this point,

we are

pleased with the organic demand we believe we are observing in the field. We have been moving quickly to establish the mechanical infrastructure, the institutional knowledge, and the experience

base that

will allow appropriate vulnerable populations, their HCPs, and broad health systems to access PEMGuard routinely. I'll now turn the call over to Bill Duke, the CFO of InVivid, to discuss our financial results and guidance.

Thank you, Mark. Turning to slide five, we ended Q1 2024 with cash and cash equivalents of $189.4 million. We did not record any PEMGuard of revenue in the first quarter as orders and shipments began in April. In April 2024, we announced that following a comprehensive strategic review, the company is improving its projected 2024 year-end cash position by approximately 20 to $25 million. Our updated cash guidance improvement was built to include the anticipated spend on 2024 incremental clinical commitments associated with our potential treatment EUA. The improvements were realized through comprehensive resource realignment, ensuring robust investment in the commercial launch of PEMGuard, and the discovery of novel monoclonal antibodies. We have recently undertaken a commitment to filing a second EUA application for PEMGuard focusing on the treatment of mild to moderate symptomatic COVID-19 for certain immunocompromised people. This is a potentially transformational opportunity for InVivid near term as we move into the summer and fall. And we consider this route as a future cornerstone for rapid development of innovative molecules. We will not, however, alter our year-end cash and top line revenue guidance, even if we achieve EUA treatment. At this point, we feel very comfortable with our near term economic opportunity and look forward to updating our estimates in the fall at the earliest. Finally, as Mark mentioned, we look forward to continuing to innovate and introduce additional novel antibodies. We have studied the time and costs associated with generating the PEMGuard clinical package that support prep and potential treatment. Going forward, we believe we can significantly reduce our clinical development time and costs, and we will look forward to sharing more details soon. As you have seen from our prior descriptions of the target population and our recently disclosed commercial pricing, these use cases represent a total addressable market measured in billions of annual revenue when considering the roughly 500,000 people in the US who are the most vulnerable and our initial focus. We are working to realize that potential and aim to expand the populations we can serve as our technology and strategy allow. With that, I'll turn the call over to Jeremy to update you on our launch.

Thanks, Bill. Moving to slide six, PEMGuard is a high value medicine for moderately to severely immunocompromised individuals who are in urgent need of protection from COVID-19. It fills a critical need not otherwise addressed in the marketplace today. Overall, we are very pleased with the strong interest we've seen thus far from patients and providers. Since authorization, we have so far received a surprising and gratifying level of unsolicited inquiries into our call center. Our field teams are having many positive interactions with our customers and are experiencing a high degree of interest in PEMGuard. Now we are going through the logistics phase of the launch

where we are managing

the processes around institution and payer access to ensure that PEMGuard is broadly and conveniently available to those whom it is authorized. We are moving to ensure that PEMGuard awareness and logistical support are in place prior to the broadest activation of HCP and patient interest in the coming months. Of note, PEMGuard represents our first generation technology. And as we will discuss later on in the call, we already have a follow-up map in BYD 2311, which we believe holds the potential to have an improved product profile. The work we are doing today with PEMGuard, we believe will pave the way for BYD 2311 to seamlessly slot in behind it and build on PEMGuard's anticipated success. Turning to slide seven, we are a little more than six weeks post-authorization and the commercial organization and function supporting it have been hard at work to execute on the PEMGuard launch. Our manufacturer and colleagues worked very quickly to have product available within a week of authorization. In parallel, we contracted with three major distributors to ensure that our customers could procure PEMGuard via their preferred procurement partner and subsequently shipped our first order. As of late, our focus has been on securing reimbursement and access. In mid-April, we announced that the US Centers for Medicare and Medicaid Services, or CMS, published two healthcare common procedure coding system codes or HCPCS codes, a Q code covering product reimbursement for PEMGuard, and a product specific M code covering the administration. This is critical because CMS provides coverage for nearly half of the moderately to severely immunocompromised people at higher risk for severe COVID-19, whom we are targeting. In parallel, our national account management team has been working to secure commercial reimbursement for PEMGuard, as well with private payers, to ensure that the other half of the moderately to severely immunocompromised people who are eligible for PEMGuard can access it. Our team of key account managers recently hit the ground running after completing extensive training, and they are now all fully deployed and calling on our roughly 1,150 targeted accounts to build awareness for the product and drive uptake. Their early focus is on securing inclusion of PEMGuard on institutional formularies as needed. We have had positive engagement, and we see institutions taking it through the formulary committee processes already, and some have already ordered product. With respect to the patient experience and access, we're putting an even greater focus on building out logistical support to assist moderate to severe immunocompromised people who are seeking PEMGuard. This work includes the creation of an online infusion site finder to help those people trying to access PEMGuard. This new tool, which will be accessible in the future on PEMGuard.com, is under active development, and in parallel, we are engaging with infusion providers outside of traditional institutions to support patient access to the product. And finally, we are excited about the potential to submit and receive an additional EUA for PEMGuard, focused on the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people, should it be granted by the FDA. Since the commercial pathway and infrastructure already exists for the antivirals, like Vecluri, we are excited to have this additional use case for the product beyond prep as another potential way to capitalize on the work done to bring PEMGuard to market. We will look forward to updating you more on our sales and relevant trends as the launch progresses. I will now turn the call over to Mark Vinkurdzon, SVP of Clinical Development and Medical Affairs.

Over to you, Mark.

Thanks, Jeremy.

It's been great to join in Vivid at a fascinating time for the company and patients in need. Turning to slide eight, as a reminder, our EUA for prep for COVID-19 in certain adults and adolescents who have moderate to severe immune compromise is based upon the ongoing Canopy Phase III clinical trial that includes two cohorts. First, we have a single arm, open label cohort, and immunocompromised subjects, the so-called cohort A. Second, there is a randomized double-blind safety cohort in people at risk of -CoV-2 infection from regular -to-face meetings with exploratory clinical event endpoints, the so-called cohort B. We have collected exploratory information on COVID events in both arms on an ongoing basis. Although obviously the lack of a placebo arm renders the interpretation of events in the cohort A a bit more opaque. Moving to slide nine, as a reminder, in order to meet the immunobridging endpoint agreed to with FDA, we dosed to very high titers and then allowed the titers to decay with ordinary antibody PK, subject to the half-life of VYD222 nalpengarda. You can well imagine that a redose will produce another major boost to titers, which we then expect will fall at a similar rate. As every dose involves a phase with very high titers, which then descend to lower levels, we look forward to seeing how we accrue any events we collect after our day 90 calculation in trough titers, perhaps prior to a second dose, a time period that may give us information that could help us calibrate dose optimization going forward. Turning to slide 10 as a reminder, we began the Canopy clinical trial going into and then through the fall, winter 2023, 2020, 24 JN.1 wave. As a result, we saw a relatively robust attack rate in our study of about three to 5%. Although Canopy was not prospectively designed or powered to demonstrate protection from symptomatic COVID-19, and that analysis of exploratory endpoints of symptomatic COVID-19 events in Canopy were unrelated to FDA's review of our EUA application, we note the events have exploratory value as we consider the titers that may be associated with various levels of protection and think about dose and product profile going forward. We have previously disclosed that in cohort B, our double blind placebo control cohort, we observed protection of 100% through day 67, a period that overlapped with very high SVNA titers. Through day 90, we saw one breakthrough infection in the Pimivibart arm compared to eight in the placebo arm, yielding a relative risk reduction of approximately 94%. As highlighted on the previous slide, while we are aware that additional cases of COVID-19 have occurred in cohort A and cohort B post day 90, we are awaiting the upcoming analysis of the second dose blinded 90 day interval that will add additional resolution to our thinking. We look forward to sharing these data later this summer. Turning to slide 11, importantly, we recently announced our intention to submit an EUA request for PEMGARDA for the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people. As described in our press release, we view this as a logical and welcome compliment to our overall serial monotherapy bridging paradigm and a reassuring reminder of the intellectual alignment between InVivid and the US FDA. The anticipated treatment EUA submission will leverage already existing data sets from our stamp and canopy clinical trials. In parallel to the anticipated submission of the EUA request, we plan to design and initiate a compact clinical trial focused on generated confirmatory safety, pharmacokinetic and clinical virology data. Importantly, treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people is a second use case for PEMGARDA and possibly follow up molecules with shorter term endpoints than PrEP, which may substantiate rapid innovation moving forward. Turning to slide 12, this additional use case is important because even with vaccination, immunocompromised people are disproportionately impacted by severe COVID-19 outcomes and remain a major driver of ongoing hospitalization and death in the US despite current small molecule treatment options. Moving to slide 13, if authorized, PEMGARDA could be a welcome addition to the therapeutic armamentarium and a valuable potential option for certain people with moderate to severe immunocompromised when alternative COVID-19 treatment options are not clinically appropriate or accessible. At present, there is no authorized antibody treatment of COVID-19 and among existing options, some are complicated by drug-drug interactions and others are mainly deployed in a hospital setting requiring burdensome repeat intravenous infusions on consecutive days. Turning to slide 14, as we have seen since the beginning of COVID therapies, treatment option utilization ebbs and flows with overall viral presence. Nonetheless, in year five of the pandemic, COVID treatments remain heavily utilized. We are moving with considerable urgency as we believe that immunobridging provides us with a more rapid and efficient pathway to deliver an important COVID-19 treatment option complimenting our efforts with PrEP. I am now pleased to turn the call to Robbie to discuss our analytics and discovery technologies.

Thank you, Mark. Good afternoon. Many of you have expressed interest in hearing more about our work on virus evolution and the confidence we have in the quality and durability of PEMGARDA and our pipeline molecules. To start on slide 15, I want to introduce VividTools, which is our in-house proprietary software that tracks virus variation across our COV-2 from multiple sources, including clinical sample sequence data and the sequencing data collected from wastewater. As a general rule, variants that become clinically relevant are detected in wastewater well in advance of their broad emergence. Wastewater data also includes sequences of viruses that do not ultimately rise to high prevalence in the clinic. But these data provide a broad view of the mutational space that has been explored by the virus over time. We use this tool for two purposes. Firstly, in furtherance of activity prediction and monitoring, but also, as you will see, increasingly to power highly proprietary discovery approaches that we think give us a unique advantage in the field. As you can see on the left side of the panel on slide 16, at InVivid, we log and analyze variation observed across the spike protein down to very low frequency polymorphic explorations. In this small excerpt, you're seeing graphs which depict the various changes on amino acid by amino acid basis across positions 403 to 432. While this view of the data allows you to appreciate multiple data sets simultaneously, the sharp eye among you may notice that some of these graphs do not have a lot of color and noise on them, whereas others do. That reflects the degree to which less or more polymorphic exploration has taken place at a given residue as the virus has evolved. By evaluating epitopic sites for our antibodies, including BYD 222, we can assess how mutable or polymorphic our epitope is. And gratifyingly, in the areas we track as part of the assigned epitope of BYD 222, we have observed polymorphic stability since the emergence of Omicron through to the present day. Turning to slide 17. Of course, once we pick an antibody to develop it, we cannot change it, and so monitoring and analysis of variation gets much more valuable when we can incorporate it into the design of our screens and the selection of our antibody candidates. In a moment, I will describe how this practice has been integrated into our pipeline, but for now, I will simply note the following. When we look at the variation across spike and RBD, the area we want to contact with a map, we see evolution, sometimes saltation or large structural shifts. And then we see reconvergence along previously documented exploratory pathways. In simplest terms, while we cannot expressly predict variation, we are beginning to better understand the nature of -CoV-2 evolution. If we can create some level of data-driven intelligence in predicting future potential changes, we can identify future theoretical or synthetics by proteins that may not even exist yet as variants, but which represent probabilistic futures for which we want to prepare. And if we can do that, we can deploy our proprietary discovery technology that takes advantage of the -through-foot, east-based MAP optimization platform from AtomMap, directing it to perform operations that would be practically impossible with less advanced technology. Turning to slide 18, what that means is that armed with information about viruses that have circulated are now circulating and then armed with synthetic depictions about what might circulate. We can execute Boolean or logic-driven discovery screens in which we direct the platform to identify predefined antibodies, all based on the original frameworks of Adantrebomab and now Pmebibar, which, for example, neutralize XBV and JN.1 and so on, but which do not interact with the residues we may worry about from our probabilistic work. We can then select those candidate antibodies and indeed confirm the activity we believe we wish them to have both against current virus, but also, which embrace the anticipation of single or multiple future convergently evolved variants. Moving to slide 19, we are looking for antibodies that are not limited by mammalian immune suites, such as we might see in convalescent serum or a mouse. We are seeking novel molecules that can go through rapid, highly efficient development paths, and in each generation of molecule, we are looking to increase our design-level confidence in resistance to variation and improve the overall pharmaceutical properties of our products. In practice, this approach started with Adantrebomab, which was made early as the maturation of a -CoV-1 antibody against Wuhan-Linse virus. The critical product attribute at that time was thought to have been achieved through conservation of ACE2 access, although the Omicron shift taught us and other sponsors that there was sufficient permissiveness in ACE2 access to make immune evasion a second critical dimension of the discovery problem. Then we go to Pmebibar, which is Adantrebomab optimized against DA.2, but leaving as a criterion backwards-looking neutralization of ancestral pre-Omicron lineages. That constraint appears to be driving, so far, a highly encouraging conservation of the Pmebibar epitope across evolution, but imposed at least a modest potency penalty on recent circulating viruses. Our next anticipated clinical candidate, BYD2311, takes Pmebibar and optimizes it further for increased potency and assessed variation resistance. We will look forward to introducing you to 2311 more fully soon, but the early profile is very encouraging as it goes to improvement over Pmebibar in terms of possible dose, therapeutic index, and route of administration. A bit earlier still in discovery, we are now integrating our forward-looking synthetic antigens to create antibodies that we believe have some inbuilt anticipatory intelligence, a process we expect to monitor and refine as we go. In these, we are now operating out past the frontier of what is, and we are actually discovering and qualifying molecules that are designed on multiple dimensions to address what we believe is likely in the future, a very unique approach in biopharmaceuticals as far as we are aware. Next, I'd like to turn it back over to Mark for some closing thoughts before we move to Q&A.

Thanks, Robbie. In summary, as shown on slide 20, we're constantly tracking, analyzing, and considering variation. We do it both to monitor the probable activity of our current drug, Pmebibar, to monitor the stability of epitopes for candidate drugs, including 2311 and others, and now also to generate analytic findings that allow us to build antibodies which anticipate probable changes and clearly retain activity. You will have and will in the future see various results of neutralization assays on our and others' antibodies. We would encourage you to interpret those data with caution. Our colleagues at AstraZeneca, on the Ebucheld fact sheet, characterized changes in neutralizing potency of less than five-fold as, quote, no change,

unquote,

which speaks to the variable nature of these assays and the tenuous, uncertain relationship between those precise assay results and overall clinical activity. Worse, when and if an assay is changed or a laboratory is switched as a vendor, comparability becomes more fraught. As a consequence, while we at InVivid will continue monitoring neutralization carefully, we will not update you all on an ad hoc basis. Rather, we will communicate our findings with the FDA and update our product fact sheet when applicable. The sum of all this work is that we believe we have excellent and growing evolutionary intelligence on -CoV-2 and a unique ability to operationalize that intelligence. Our work can never be perfect as we are up against Mother Nature and she always has tricks up her sleeve. However, we are highly encouraged by our recent progress in our basic science, our clinical development, our growing regulatory alignment, and our commercial efforts. Our goal with innovation over time will be to substantially expand the populations to whom we can offer COVID-19 protection and treatment, to improve the profile of our products, and thereby to substantially increase the medical value of our products for patients and providers, and therefore our value creation for shareholders. I'd like to ask the operator to open the line for questions.

Thank you. At this time, we will conduct the question and answer session. Please stand by while we compile the Q&A roster. Our first question comes from the line of Maxwell Scor of Morgan Stanley. Your line is now open.

Great, thank you, and congratulations on the progress. So, as far as, can you elaborate a bit more on your marketing strategy, including whether you're exploring -to-consumer campaigns, and which physician specialty is most likely to prescribe PEMGARDA? And then finally, you announced plans to initiate a compact clinical trial. I'm wondering how you'll leverage these data, and whether you're running this trial in response to specific FDA feedback. Thank you.

Thanks, Max. Let me quickly touch on the second question you raised first, and I'll ask Mark to add anything I forgot, which is to say, a reference to a compact trial is, I think, described a bit in our original press release, but the basis for EUA submission is largely analytics and a little bit of incremental work from our prior clinical development work, stamp and canopy, specifically, as it goes to the treatment EUA, which I think is what you're

referring to.

So, the nature of that confirmatory study embraces elements of pharmacokinetic safety and clinical virology. That study is under active development. I'm sure, as we refine those elements, we'll share some more details with you, but very quickly. Mark, did I leave anything off of that? No,

it's, I mean, just to dovetail on what you said, it's really gonna be the evaluation, first and foremost, of that treatment emergent resistance, if any, to Pemivibard, and the collection of that safety and PK data. So, largely incremental to the studies that we've already done.

So, I think Max, Jeremy can now give you a little more color on EUA, which is a pretty unique concept in pharmaceuticals, and I think has some boundaries and advantages that bear on your specific question about marketing.

Yeah, thanks, Max and Mark, for the introduction here. So, I would say the early days were focused on raising HCP awareness for the product, and that's a really critical part, because if patients go in to access a product, and the HCP knows nothing about it, then it kind of ends up at a dead end. So, early days were focused on that as part of the launch. We have not ruled out not doing DTC in the future, and we're exploring that, and we do have some targeted patient campaigns. What we also know a little bit about patients is these kind of sick, sick patients that we see, the immunocompromised, are very active in their management of their health. And so, we've seen a lot of organic interest online, in chat groups, et cetera, where there's a fair amount of interest in trying to access the product already. So, we feel sometimes the patients are actually a little bit ahead of the HCPs in this regard, and we really do want to

inform the HCPs early on. So,

that's the

primary focus around the time of launch, and we'll explore expanding beyond that as time progresses.

Helpful, thank you.

One moment for our next question. Thank you. Our next question comes from the line of Patrick Trujillo of HC, Wainwright & Co. Your line is now open.

Thanks, good evening, and congrats on all the progress at the launch and pipeline. Just a couple of follow-up questions from me. The first is, I think it was noted that the reimbursement codes, Q code and M code, cover reimbursement for half the moderate to severe immunocompromised people at highest risk for severe COVID-19 that you're targeting. So, I'm wondering, how do we think about reimbursement for the other half of the target patient population, timing of reimbursement, and just how we should anticipate kind of the launch going with that other half? And then, separately, can you discuss the potential approval pathway for Pemgarda's treatment in immunocompromised individuals, and when you would envision being able to submit for an EOA and maybe clarify the timeline, including time to submission to potential authorization? And then, separately, just how meaningful you anticipate this label expansion may be for peak sales potential Pemgarda?

Let me again, this is Mark, let me again start with the second one, and then I'll pass it back to Jeremy on your coverage question. You know, look, I think in our press release, we explicitly said that our submission of EOA would be imminent in our language. That is generally a timeframe that would embrace weeks, let's say, rather than months or quarters, which would have caused us to pick those words instead. So, as we've tried to convey, this is an exercise rooted in intellectual alignment that draws from common material, common clinical experience as our PrEP EOA. At some level, all of these use cases are driven by SVNA titer, and if you think back to evade and stamp the, let's call them, parent clinical studies that leveraged Adentrevimab, the same dose, the same route of administration, the same titers in effect substantiated both a PrEP and a treatment use case. And so, what we're simply doing is we're moving that fundamental posture into the broader Pemgarda program while simultaneously noting that it is a potentially very interesting addition to future antibodies, which of course have been traditionally highly effective in both use cases. So, hope that helps and stay tuned. Obviously, we hope to be back to you with more color shortly. Jeremy, back to the CMS and coverage. Yeah,

on the commercial reimbursement side, we have our national account manager team out there earnestly working away and getting that for us. We understand the criticality of it given the other half of the population, as you mentioned. And so, we're encouraged by the initial engagement we're getting, but of course there's process and time that formularies

need to go through, the payers go through on their formularies, so we're working through that right now. But more to come as we go through this launch.

Great, thank you so much.

One moment for our next question. Thank you. Our next question comes from the line of Evan Wang of Guggenheim Securities. Your line is now open.

Hey guys, T for me. You know, with some of the pipeline development, I know you guys spent some time on the Scarberry Engine next gen products and how you will be approaching with zero approach going forward. So, it seems like there's been plenty of discussion with the FDA recently, just with the support of the UA for PrEP and then with these new treatment discussions. So, can you help provide some framework around the development for VUID 2311 and how you're thinking about development there? And then second, again on the treatment opportunity, just wondering how we should be thinking about this opportunity understanding tax-flow within the vocabulary are pretty robust markets, but given that the language is around alternative treatment or alternative options, when alternative options are not appropriate or accessible. Thanks.

Hey Evan, this is Mark. You know, I think the fun part of defining and leading a brand new field of medicine is probably a little bit of the frustrating part. For you as you look for specificity and precision, that is as you know, the topic of ongoing dialogue and collaboration. So, you know, when we're in a position to tell you exactly how we think these things will look, we'll certainly tell you. As now, what we've experienced over I would say a 12 to 18 month period starting with, it actually goes all the way back to the December FDA EMA joint discussion on the use of surrogates for rapid trialing of COVID-19 antibody therapeutics and prophylactics. What we are watching is a growing congruence and a growing concordance that we believe opens up certain novel pathways. And we are gonna be designing those in real time. And indeed that's what has been going on. And it is not meant to be evasive or not give you the color you're looking for, but rather to note these things are evolving as in vivid builds the real opportunities to evolve them. We have PEMGARDA, hence we have an opportunity to use it more broadly. What we have noticed with the FDA is they are very thoughtful, very engaged and very attuned to the magnitude of the unmet needs. And so as we continue and expand that collaboration as noted in some of the prepared remarks, we're really looking forward to continuing to innovate these pathways and establish bespoke and proprietary pathways that may be to some extent really enabled by our unique molecules and our unique discovery engine. So that is what you're really watching in real time. And I think we're looking forward over the next weeks and months to seeing how this new avenue takes shape. And so on treatment, I'll ask Mark to comment a little more on what he sees as the opportunity, but we elected to not change our guidance. So we're probably not gonna give you the quantitation you would hope on the size of the opportunity. However, it is something about which we are quite excited.

Thanks, Mark. This is Mark's partner in crime over here. And I've been a drug developer for almost 30 years and what I can say is, we're gonna certainly iterate and optimize based upon the skeletal framework outlined by the FDA today, not only for prevention, but also for treatment. And where I do think that this potentially fits is we certainly know remdesivir is very burdensome to not only healthcare practitioners, but also to patients. The multi-infusions that they need within a very, very short period of time, and again, are mostly relegated to those in-hospital use cases. And certainly, Paxlovid will not go away, but Paxlovid with their drug-drug interactions and with a lot of the breakthrough symptomology due to the fact that they're really not being able to abolish the titers to a level that perhaps MAP gets you to, provides I think a very, very nice use case there, especially in those patients who are immunocompromised and have a lot of comorbid conditions as well as on a lot of other drugs that could interact unfavorably with the current drugs that are available.

Thanks.

One moment for our next question. Thank you. Our next question comes from the line of Michael Yee of Jeffreys. Your line is now open.

Hi, thanks for taking our question. This is Jenna on for Mike. Our question is, what magnitude of orders or potential orders are you seeing right now? When will they come in? Have you shipped anything? And when would you start booking sales? Thank you.

Thanks for the question. You know, we have made some very preliminary disclosures in prior press releases that I'll ask you to take a read through one last time, but at this point, we're not gonna go into any incremental detail. This is the early phase of the launch. It is very quickly gonna be the middle phase of the launch. And I think as we look forward to the summer and then the fall, we're obviously gonna be in a position to give you some feedback and some information that is useful to you, right? At this point, I think it's a little bit early, although we over here are quite encouraged. I don't know that anything we could respond to you with today would be particularly informative as it goes to understanding how the balance of the year is likely to play out. So stay tuned and we are looking forward just as you are to getting into more of that detail as the launch progresses.

Thank you. That's helpful.

I am showing no further questions at this time. I would now like to turn it back to Mark Aliyah, Chairman of Invivid Board of Directors and Chairman of the Executive Committee of the Board for closing remarks.

Thank you. And thanks to all of you for joining the call today and for your interest in Invivid.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.

I do now decide to close the make table filming . . . . . . . . . . . . . . . . . . .

. . . .

. . .

. . . . . . . . . . .

. . . . . .

. . . . . . . .

. . . . . . . . . . . . .

. . . . . . . . . . . . . .

. . . .

. . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. .

. .

. . . . . . .

. .

. . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . .

. . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

.

. . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . .

. . . . . . . . . . . . . . . . . . . . . .